Insight Molecular Diagnostics Inc.
IMDX- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001642380
No open-market purchases or sales by Insight Molecular Diagnostics Inc. insiders were filed in the last 90 days; 40 institutions reported holding it in 13F filings for Q2 2026, worth $108.9M in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Insight Molecular Diagnostics Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 25 | 23 | −2 |
| Shares | 4.37M | 7.14M | +2.77M (+63.5%) |
| Value | $12.8M | $21.1M | +$8.27M (+64.6%) |
New holders (3)
Institutions that held Insight Molecular Diagnostics Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| FNY Investment Advisers, LLC | 23,654 | $69.0K | 0.05% |
| Northern Trust Corp | 17,346 | $51.2K | 0.00% |
| Coppell Advisory Solutions LLC | 10 | $30 | 0.00% |
Sold out (5)
Institutions that held Insight Molecular Diagnostics Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| NBC Securities, Inc. | 150 | $1.00K |
| Wells Fargo & Company | 61 | $179 |
| Comerica Bank | 23 | $67 |
| FMR LLC | 13 | $38 |
| Royal Bank of Canada | 80 | $0 |